Allied Biotech Corp AI Stock Analysis
Allied Biotech Corp (1780) AI Stock Analysis
Allied Biotech Corp
(TPEx:1780)
Allied Biotech earns a solid score driven primarily by improving fundamentals: expanding margins, a 28% jump in net income, strong free cash flow covering 85% of earnings, and meaningful debt reduction that lowered leverage to 0.59 debt-to-equity. Valuation reinforces the case, with a modest 8.1x P/E and a generous 5.3% dividend yield. The main drag is technical weakness — the stock trades below all key moving averages with a negative MACD, indicating a persistent downtrend. Secondary risks include historically volatile margins and only mid-single-digit revenue growth, so continued execution on profitability and a reacceleration in growth are needed to change the trend.
Allied Biotech Corp (1780) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.59B
- Dividend Yield
- 5.27%
- Average Volume (3M)
- 76.53K
- Price to Earnings (P/E)
- 8.0
- Beta (1Y)
- 0.28
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- TW
- Employees
- 40
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Allied Biotech Corp Business Overview & Revenue Model
Company Description
Allied Biotech Corporation operates as a global producer and supplier specializing in carotenoids. The company's diverse product portfolio features key carotenoids such as: Beta-Carotene, known for imparting vibrant yellow to reddish-orange hues acro...
Allied Biotech Corp Financial Statement Overview
Summary
Allied Biotech shows a solid and improving financial profile. Revenue grew about 5% to NT$849.5 million, with margins expanding across the board (gross 36.3%, operating 21.4%, net 15.2%) and net income up roughly 28% to NT$129.5 million. The balance sheet strengthened as debt fell to NT$733.5 million and debt-to-equity dropped to 0.59, while ROE improved to 10.5%. Cash flow is the standout, with operating cash flow of NT$217.1 million and free cash flow of NT$183.5 million covering about 85% of net income. Offsetting these strengths are a volatile multi-year margin and cash flow history, only modest revenue growth, and returns that remain mid-range for the sector.
Income Statement
72PositiveBalance Sheet
74PositiveCash Flow
76Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 916.48M | 849.51M | 806.92M | 720.43M | 716.75M | 676.76M |
| Gross Profit | 363.14M | 308.61M | 258.38M | 246.44M | 271.05M | 258.05M |
| EBITDA | 217.64M | 242.44M | 205.93M | 204.79M | 270.55M | 94.06M |
| Net Income | 285.89M | 129.46M | 100.94M | 97.41M | 146.74M | 13.04M |
Balance Sheet | ||||||
| Total Assets | 2.56B | 2.09B | 2.26B | 2.08B | 2.18B | 2.44B |
| Cash, Cash Equivalents and Short-Term Investments | 1.22B | 853.91M | 987.24M | 724.77M | 793.00M | 1.14B |
| Total Debt | 752.48M | 733.52M | 955.38M | 796.61M | 838.04M | 1.25B |
| Total Liabilities | 1.04B | 857.19M | 1.06B | 910.12M | 999.40M | 1.36B |
| Stockholders Equity | 1.52B | 1.23B | 1.20B | 1.17B | 1.18B | 1.08B |
Cash Flow | ||||||
| Free Cash Flow | 171.66M | 183.55M | 196.98M | 89.71M | 109.62M | 22.44M |
| Operating Cash Flow | 202.53M | 217.13M | 223.79M | 137.62M | 164.27M | 72.43M |
| Investing Cash Flow | -52.25M | -89.49M | 70.55M | -40.94M | 219.02M | -180.94M |
| Financing Cash Flow | 54.77M | -319.33M | 64.94M | -158.33M | -462.00M | 164.24M |
Allied Biotech Corp Peers Comparison
Overall Rating
- TW:178071Outperform
TW:173363Neutral
TW:176240Underperform
TW:665738Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1780 | 71Outperform | TWD 2.59B | 8.03 | ― | 5.27% | ― | ― |
| TW:1733 | 63Neutral | TWD 2.85B | 15.05 | ― | 4.55% | -5.22% | 22.94% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1762 | 40Underperform | TWD 2.39B | -35.22 | ― | 0.62% | -20.25% | 81.66% |
| TW:6657 | 38Underperform | TWD 2.69B | -8.88 | ― | ― | -4.36% | 1.97% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1780 | Allied Biotech Corp | 23.70 | 6.00 | 33.88% | |
| TW:1733 | Apex Biotechnology Corp. | 28.60 | -1.34 | -4.47% | |
| TW:1762 | Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A | 32.75 | 7.80 | 31.26% | |
| TW:6657 | Energenesis Biomedical Co., Ltd. | 30.00 | -11.10 | -27.01% | |
| TW:6918 | A Plus Biotechnology Co Ltd | 74.90 | -7.73 | -9.36% | |
| TW:6955 | Bonraybio Co. Ltd. | 87.30 | -46.58 | -34.79% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026